Athos has developed a unique platform able to identify and develop novel drugs for patients with autoimmune and chronic inflammatory diseases. This approach is based on the integration of medicinal chemistry and systems biology through machine learning.

• First, we identify novel factors related to the disease pathobiology based on the integration of human clinical and molecular datasets from patients with autoimmune diseases.
• Second, we synthesize small molecules based on our computational medicinal chemistry platform.

Taken together these two approaches, combined with a machine learning algorithm, identify the best compounds that safely and efficiently target key disease factors.